BioCentury
ARTICLE | Clinical News

Agenus reports Phase I data for AEGN1884 in solid tumors

June 30, 2017 7:00 PM UTC

Agenus Inc. (NASDAQ:AGEN) reported interim data from 16 evaluable patients with advanced or refractory solid tumors in a Phase I trial showing that 0.1, 0.3, 1 and 3 mg/kg doses of AGEN1884 led to no dose-limiting toxicities (DLTs). Additionally, 0.1 mg/kg AGEN1884 led to a partial response in a patient with angiosarcoma at week 33, with a 92% reduction in tumor volume. Data were presented at the American Society of Clinical Oncology meeting in Chicago.

The open-label, dose-escalation, U.S. trial is enrolling about 48 patients and is evaluating DLTs, maximum tolerated dose (MTD) and pharmacokinetics as its primary endpoints. Secondary endpoints include objective response rate (ORR), duration of response, progression-free survival (PFS) and overall survival (OS)...